Granite Bio

About Granite Bio

Granite Bio is a biotechnology company focused on developing first-in-class therapeutic antibodies targeting chronic inflammatory diseases. The company operates in the biopharmaceutical market, primarily serving patients with conditions such as inflammatory bowel disease (IBD), autoimmunity, and fibrosis. Granite Bio's business model revolves around leveraging proprietary patient profiling to identify novel disease biology nodes, which informs the development of their lead assets, GRT 001 and GRT 002. These assets are designed to deplete pathogenic pro-inflammatory monocytes and target novel therapeutic nodes, respectively. The company generates revenue through strategic partnerships and venture capital funding, having secured significant investments from Versant Ventures, Novartis Venture Fund, Forbion, and Sanofi Ventures. Granite Bio is currently advancing its pipeline through preclinical and clinical development stages, with a focus on achieving regulatory approvals and expanding its clinical trials. The company's strategic integration into the Ridgeline Discovery Engine supports its research and development efforts, positioning it to address the significant global burden of chronic inflammatory diseases.